Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Expertise in Melanoma: HELP
Kevin B. Kim
Based on 80 articles published since 2008
||||
Expertise Level
The expertise of Kevin B. Kim ranks in the
  • Top 0.033%
  • ... of 99,743 published authors worldwide on Melanoma
  • ... from 2008 through 2018
  • ... based on contributions to 80 articles on the topic.
Graphical view (beta)
Uncounted papers?
Get your prestigious
World Expert badge
similar to this:
 
Aliases Kim, Kevin   ·   Kim, Kevin B
Work Locations
Details
Most likely:    University of California San Francisco   Contact    
2017
  • Beth Israel Deaconess Medical Center, Boston, Massachusetts. · Center for Cancer Precision Medicine/Dana-Farber Cancer Institute and the Broad Institute, Boston, Massachusetts. · Broad Institute of MIT and Harvard, Cambridge, Massachusetts. · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. · Dana Farber Cancer Institute, Boston, Massachusetts. · Massachusetts General Hospital, Boston, Massachusetts. · Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania. · California Pacific Medical Center Research Institute, San Francisco, California. · Vanderbilt-Ingram Cancer Center, Vanderbilt, Tennessee. · University Hospital, Zurich, Switzerland. · Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts. · Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. · Novartis Pharma AG, Basel, Switzerland. · Georgetown-Lombardi Comprehensive Cancer Center, Washington, District of Columbia. · Pubmed 28719152
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · Moffitt Cancer Center, 12902 USF Magnolia Dr., Tampa, FL, 33612, USA. · Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · California Pacific Medical Center, 2323 Sacramento St. #2, San Francisco, CA, 94115, USA. · The University of Texas Banner MD Anderson Cancer Center, 2946 E Banner Gateway Dr., Gilbert, AZ, 85234, USA. · Pubmed 28612140
  • Department of Medical Oncology, Moffitt Cancer Center, Tampa, Florida. · Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. · Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas. · Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. · Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. · Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. · Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. · Department of Internal Medicine, Baylor College of Medicine, Houston, Texas. · Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas. · Melanoma Clinical Research Program, California Pacific Medical Center, San Francisco, California. · Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas. · Pubmed 27911979
2016
  • Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston. · Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston. · Beth Israel Deaconess Medical Center, Boston, Massachusetts. · Departments of Pathology and Translational and Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston. · Broad Institute, Cambridge, Massachusetts. · Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston7Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston. · Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston. · Massachusetts General Hospital, Boston. · California Pacific Medical Center Research Institute, San Francisco. · Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston11Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston. · Pubmed 27124486
2015
  • Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA. · Department of Melanoma Medical Oncology, The University of Texas-MD Anderson Cancer Center, Houston, TX, USA. · Department of Medicine Statistics Core, University of California Los Angeles, Los Angeles, CA, USA. · St. Luke's Medical Center Cancer Center, Houston, TX, USA. · Department of Medicine, Division of Hematology/Oncology, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA, USA. · Department of Radiology, University of California Los Angeles, Los Angeles, CA, USA. · Department of Melanoma Medical Oncology, The University of Texas-MD Anderson Cancer Center, Houston, TX, USA; California Pacific Medical Center, San Francisco, CA, USA. · Department of Medicine, Division of Hematology/Oncology, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA, USA. Electronic address: · Pubmed 26364516
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. · California Pacific Medical Center for Melanoma Research and Treatment, San Francisco Oncology Associates, 2333 Buchanan St., San Francisco, CA, 94115, USA. · Pubmed 25962795
2016
  • Georgina V. Long, Melanoma Institute Australia; The University of Sydney; Richard F. Kefford, Melanoma Institute Australia; The University of Sydney; Macquarie University, Sydney; Westmead Hospital, Westmead; Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia; Jeffrey S. Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute/Tennessee Oncology; Kevin B. Kim, California Pacific Medical Center; Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, Karl Lewis, University of Colorado; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Jeffrey A. Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Elizabeth Cunningham, Merck; Peng Sun, Amy S. Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia, PA; Donald Lawrence and Kiran Patel, Incyte Corporation, Wilmington, DE; and Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA. · Georgina V. Long, Melanoma Institute Australia; The University of Sydney; Richard F. Kefford, Melanoma Institute Australia; The University of Sydney; Macquarie University, Sydney; Westmead Hospital, Westmead; Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia; Jeffrey S. Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute/Tennessee Oncology; Kevin B. Kim, California Pacific Medical Center; Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, Karl Lewis, University of Colorado; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Jeffrey A. Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Elizabeth Cunningham, Merck; Peng Sun, Amy S. Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia, PA; Donald Lawrence and Kiran Patel, Incyte Corporation, Wilmington, DE; and Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA. · Pubmed 26811525
2014
  • Douglas B. Johnson and Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Keith T. Flaherty and Donald P. Lawrence, Massachusetts General Hospital Cancer Center, Boston MA; Jeffrey S. Weber and Geoffrey T. Gibney, Moffitt Cancer Center, Tampa, FL; Kevin B. Kim and Gerald S. Falchook, University of Texas MD Anderson Cancer Center, Houston, TX; Richard F. Kefford and Georgina V. Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales; Jonathan Cebon, Joint Ludwig-Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia; Omid Hamid, Angeles Clinic and Research Institute, Los Angeles; Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA; William H. Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Robert R. McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Karl Lewis and Rene Gonzalez, University of Colorado, Denver, CO; and Kiran Patel, Incyte, Wilmington, DE. · Douglas B. Johnson and Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Keith T. Flaherty and Donald P. Lawrence, Massachusetts General Hospital Cancer Center, Boston MA; Jeffrey S. Weber and Geoffrey T. Gibney, Moffitt Cancer Center, Tampa, FL; Kevin B. Kim and Gerald S. Falchook, University of Texas MD Anderson Cancer Center, Houston, TX; Richard F. Kefford and Georgina V. Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales; Jonathan Cebon, Joint Ludwig-Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia; Omid Hamid, Angeles Clinic and Research Institute, Los Angeles; Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA; William H. Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Robert R. McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Karl Lewis and Rene Gonzalez, University of Colorado, Denver, CO; and Kiran Patel, Incyte, Wilmington, DE. · Pubmed 25287827
2013
  • Paolo A. Ascierto, Ester Simeone, Instituto Nazionale Tumori Fondazione "G. Pascale," Napoli, Italy; David Minor, California Pacific Center for Melanoma Research and Treatment, San Francisco; Antoni Ribas, Jonsson Comprehensive Cancer Center, University of California, Los Angeles; Omid Hamid, Experimental Therapeutics/Immunotherapy, The Angeles Clinic and Research Institute, Los Angeles, CA; Anne O'Hagan, Niki Arya, Mary Guckert, Anne-Marie Martin, Jolly Mazumdar, Vicki L. Goodman, GlaxoSmithKline Oncology, Collegeville; Ravi Amaravadi, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Kevin B. Kim, The University of Texas MD Anderson Cancer Center, Houston, TX; Celeste Lebbe, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Paris, Université Paris Diderot, Paris; Jean-Jacques Grob, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Hôpital Timone, Marseille, France; Dirk Schadendorf, University Hospital Essen, Essen; Tabea Wilhelm, Uwe Trefzer, Charité-Universitätsmedizin, Berlin, Germany; Richard F. Kefford, Georgina V. Long, Westmead Hospital and Melanoma Institute Australia, University of Sydney, Sydney, Australia. · Pubmed 23918947
Probable:    University of Texas Houston   Contact    
2017
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · Moffitt Cancer Center, 12902 USF Magnolia Dr., Tampa, FL, 33612, USA. · Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · California Pacific Medical Center, 2323 Sacramento St. #2, San Francisco, CA, 94115, USA. · The University of Texas Banner MD Anderson Cancer Center, 2946 E Banner Gateway Dr., Gilbert, AZ, 85234, USA. · Pubmed 28612140
2015
  • The University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Sarah Cannon Research Institute at HealthONE, Denver, CO, USA. · Former employees of Eisai Inc., Woodcliff Lake, NJ, USA. · Eisai Inc., Oncology, Woodcliff Lake, NJ, USA. · Mary Crowley Cancer Research Center, Dallas, TX, USA. · Pubmed 26503473
  • The University of Texas MD Anderson Cancer Center, Houston, Texas. · The University of Texas MD Anderson Cancer Center, Houston, Texas. · Sarah Cannon Research Institute at HealthONE, Denver, Colorado. · Eisai Inc., Oncology, Woodcliff Lake, New Jersey. · Former employees of Eisai Inc., Woodcliff Lake, New Jersey. · Mary Crowley Cancer Research Center, Dallas, Texas. · Pubmed 26169970
  • Vanderbilt-Ingram Cancer Center, Vanderbilt University, 2220 Pierce Avenue #777, Nashville, TN 37232, USA. Electronic address: · Abramson Cancer Center and the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA. Electronic address: · Peter MacCallum Cancer Centre, 2 St Andrews Place, East Melbourne, Vic 3002, Australia. Electronic address: · Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA. Electronic address: · Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Electronic address: · Vanderbilt-Ingram Cancer Center, Vanderbilt University, 2220 Pierce Avenue #777, Nashville, TN 37232, USA. Electronic address: · Jonsson Comprehensive Cancer Center, University of California, Los Angeles, 11-934 Factor Bldg., 10833 Le Conte Ave., Los Angeles, CA 90095-1782, USA. Electronic address: · Peter MacCallum Cancer Centre, 2 St Andrews Place, East Melbourne, Vic 3002, Australia. Electronic address: · The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Electronic address: · Jonsson Comprehensive Cancer Center, University of California, Los Angeles, 11-934 Factor Bldg., 10833 Le Conte Ave., Los Angeles, CA 90095-1782, USA. Electronic address: · Plexxikon Inc., 91 Bolivar Drive, Berkeley, CA 94710, USA. Electronic address: · Plexxikon Inc., 91 Bolivar Drive, Berkeley, CA 94710, USA. Electronic address: · The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Electronic address: · Pubmed 25980594
  • Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA. · Department of Melanoma Medical Oncology, The University of Texas-MD Anderson Cancer Center, Houston, TX, USA. · Department of Medicine Statistics Core, University of California Los Angeles, Los Angeles, CA, USA. · St. Luke's Medical Center Cancer Center, Houston, TX, USA. · Department of Medicine, Division of Hematology/Oncology, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA, USA. · Department of Radiology, University of California Los Angeles, Los Angeles, CA, USA. · Department of Melanoma Medical Oncology, The University of Texas-MD Anderson Cancer Center, Houston, TX, USA; California Pacific Medical Center, San Francisco, CA, USA. · Department of Medicine, Division of Hematology/Oncology, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA, USA. Electronic address: · Pubmed 26364516
  • Department of Investigational Cancer Therapeutics - a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · Foundation Medicine, 150 Second Street, Cambridge, MA, 02141, USA. · Department of Investigational Cancer Therapeutics - a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · Department of Investigational Cancer Therapeutics - a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · Foundation Medicine, 150 Second Street, Cambridge, MA, 02141, USA. · Department of Investigational Cancer Therapeutics - a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · Foundation Medicine, 150 Second Street, Cambridge, MA, 02141, USA. · Center for Personalized Cancer Therapy, Moores Cancer Center, The University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA, 92093, USA. · Pubmed 25886620
  • Department of Pathology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. · Department of Surgical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. · Department of Biostatistics, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. · Department of Melanoma Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. · Department of Pathology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA; Department of Dermatology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. · Department of Surgical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA; Department of Cancer Biology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. · Department of Melanoma Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA; Department of Systems Biology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. · Department of Hematopathology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. · Department of Systems Biology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. · Department of Experimental Therapeutics, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. · Department of Surgical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA; Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. · Department of Melanoma Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA; Department of Systems Biology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. Electronic address: · Pubmed 25148578
2014
  • Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ. · Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ. · Pubmed 25267741
  • Division of Cancer Medicine, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. · Melanoma Institute Australia and University of Sydney, New South Wales, Australia. Westmead Institute for Cancer Research, Westmead Millennium Institute, and Department of Medical Oncology, Westmead Hospital, Sydney, New South Wales, Australia. · Moores Cancer Center, University of California San Diego, La Jolla, California. · Division of Cancer Medicine, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. · GlaxoSmithKline Medicines Research Unit, Prince of Wales Hospital, Randwick, New South Wales, Australia. · Cancer Clinical Trials Unit, Royal Adelaide Hospital and University of Adelaide, Adelaide, South Australia, Australia. · Experimental Therapeutics/Immunotherapy, The Angeles Clinic and Research Institute, Los Angeles, California. · Drug Development Unit, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee. · Cancer Council Trials and Sir Charles Gairdner Hospital and University of Western Australia, Perth, Western Australia, Australia. · Division of Medical Oncology, New York University School of Medicine, New York, New York. · Prince of Wales Clinical School, University of New South Wales, Randwick, Australia. · GlaxoSmithKline Research and Development, Philadelphia, Pennsylvania and Research Triangle Park, North Carolina. · Melanoma Institute Australia and University of Sydney, New South Wales, Australia. Westmead Institute for Cancer Research, Westmead Millennium Institute, and Department of Medical Oncology, Westmead Hospital, Sydney, New South Wales, Australia. · Pubmed 24958809
  • University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: · Pubmed 24485878
2013
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. · Pubmed 23248257
2012
  • Department of Melanoma Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas 77030, USA. · Pubmed 22668797
  • The University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Pubmed 22124101
2011
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. · Pubmed 21976540
2009
  • Department of Melanoma Medical Oncology, M. D. Anderson Cancer Center, The University of Texas, Houston 77030, Texas, USA. · Pubmed 19430405
  • Department of Melanoma Medical Oncology, Unit 430, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. · Pubmed 19002462
2014
  • University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Pubmed 24259661
  • Douglas B. Johnson and Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Keith T. Flaherty and Donald P. Lawrence, Massachusetts General Hospital Cancer Center, Boston MA; Jeffrey S. Weber and Geoffrey T. Gibney, Moffitt Cancer Center, Tampa, FL; Kevin B. Kim and Gerald S. Falchook, University of Texas MD Anderson Cancer Center, Houston, TX; Richard F. Kefford and Georgina V. Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales; Jonathan Cebon, Joint Ludwig-Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia; Omid Hamid, Angeles Clinic and Research Institute, Los Angeles; Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA; William H. Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Robert R. McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Karl Lewis and Rene Gonzalez, University of Colorado, Denver, CO; and Kiran Patel, Incyte, Wilmington, DE. · Douglas B. Johnson and Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Keith T. Flaherty and Donald P. Lawrence, Massachusetts General Hospital Cancer Center, Boston MA; Jeffrey S. Weber and Geoffrey T. Gibney, Moffitt Cancer Center, Tampa, FL; Kevin B. Kim and Gerald S. Falchook, University of Texas MD Anderson Cancer Center, Houston, TX; Richard F. Kefford and Georgina V. Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales; Jonathan Cebon, Joint Ludwig-Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia; Omid Hamid, Angeles Clinic and Research Institute, Los Angeles; Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA; William H. Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Robert R. McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Karl Lewis and Rene Gonzalez, University of Colorado, Denver, CO; and Kiran Patel, Incyte, Wilmington, DE. · Pubmed 25287827
  • aHealth Science Center, University of Oklahoma, Oklahoma City, Oklahoma Departments of bMelanoma Medical Oncology cPalliative Care and Rehabilitative Medicine dBiostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. · Pubmed 24743052
  • Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Pubmed 25030020
  • The University of Texas MD Anderson Cancer Center, Department of Melanoma Medical Oncology , Unit 430, 1515 Holcombe Blvd, Houston, TX 77030 , USA. · Pubmed 24720932
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. · Pubmed 24617955
  • Departments of *Pathology, †Melanoma Medical Oncology, ‡Head and Neck Surgery, and §Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas. · Pubmed 23812018
2013
  • The University of Texas MD Anderson Cancer Center, Dermatology, 1515 Holcombe Blvd, Houston, TX 77030, USA. · Pubmed 23800008
  • Paolo A. Ascierto, Ester Simeone, Instituto Nazionale Tumori Fondazione "G. Pascale," Napoli, Italy; David Minor, California Pacific Center for Melanoma Research and Treatment, San Francisco; Antoni Ribas, Jonsson Comprehensive Cancer Center, University of California, Los Angeles; Omid Hamid, Experimental Therapeutics/Immunotherapy, The Angeles Clinic and Research Institute, Los Angeles, CA; Anne O'Hagan, Niki Arya, Mary Guckert, Anne-Marie Martin, Jolly Mazumdar, Vicki L. Goodman, GlaxoSmithKline Oncology, Collegeville; Ravi Amaravadi, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Kevin B. Kim, The University of Texas MD Anderson Cancer Center, Houston, TX; Celeste Lebbe, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Paris, Université Paris Diderot, Paris; Jean-Jacques Grob, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Hôpital Timone, Marseille, France; Dirk Schadendorf, University Hospital Essen, Essen; Tabea Wilhelm, Uwe Trefzer, Charité-Universitätsmedizin, Berlin, Germany; Richard F. Kefford, Georgina V. Long, Westmead Hospital and Melanoma Institute Australia, University of Sydney, Sydney, Australia. · Pubmed 23918947
  • F. Stephen Hodi, Anita Giobbie-Hurder, Philip Friedlander, Jason J. Luke, Katherine A. Zukotynski, Jeffrey T. Yap, Annick D. Van den Abbeele, and George D. Demetri, Dana-Farber Cancer Institute; Jonathan A. Fletcher, Meijun Zhu, and Adrian Marino-Enriquez, Brigham and Women's Hospital; Donald Lawrence, Keith T. Flaherty, and David E. Fisher, Massachusetts General Hospital, Boston, MA; Christopher L. Corless, Michael C. Heinrich, and Carol Beadling, Portland Veterans Administration Medical Center and Oregon Health & Science University, Portland, OR; Philip Friedlander, Mount Sinai Medical Center, New York, NY; Rene Gonzalez, University of Colorado Cancer Center, Aurora, CO; Jeffrey S. Weber, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Thomas F. Gajewski, University of Chicago, Chicago, IL; Steven J. O'Day, Beverly Hills Cancer Center, Beverly Hills, CA; Kevin B. Kim, The University of Texas MD Anderson Cancer Center, Houston, TX; Frances A. Collichio, The University of North Carolina at Chapel Hill, Chapel Hill, NC; and Marc S. Ernstoff, Geisel School of Medicine and Norris Cotton Cancer Center, Hanover, NH. · Pubmed 23775962
  • M.D. Anderson Cancer Center, University of Texas, Houston, TX 77054, USA. · Pubmed 23603862
  • Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. · Pubmed 22972589
  • Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. · Pubmed 23922205
  • Departments of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. · Pubmed 23358426
2012
  • The University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Pubmed 22394161
  • Departments of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. · Pubmed 23032743
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. · Pubmed 22809251
  • Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Pubmed 22805292
  • Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. · Pubmed 22608338
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. · Pubmed 22274951
  • Departments of Melanoma Medical Oncology, Systems Biology, Biostatistics, Pathology, Experimental Therapeutics, and Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. · Pubmed 22223528
  • Department of Melanoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77054, USA. · Pubmed 22584956
  • The University of Texas-Houston Medical School, Houston, TX, USA. · Pubmed 22395592
  • Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. · Pubmed 22180178
2011
  • Departments of aMelanoma Medical Oncology bBioinformatics cNursing, MD, Anderson Cancer Center, University of Texas, Houston, Texas, USA. · Pubmed 21102360
  • Department of Melanoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA. · Pubmed 21738104
  • Department of Melanoma Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA. · Pubmed 21632855
  • Department of Melanoma Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. · Pubmed 20978276
  • Department of Melanoma/Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. · Pubmed 21169870
  • Departments of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. · Pubmed 21150567
  • Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77054, USA. · Pubmed 20960525
2010
  • Department of Melanoma Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA. · Pubmed 20881508
  • Department of Melanoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA. · Pubmed 20859231
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. · Pubmed 19952963
2009
  • Department of Melanoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, 1515 Holcombe Building, Unit 430, Houston, TX 77030, USA. · Pubmed 19521262
  • Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. · Pubmed 19506454
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. · Pubmed 19440934
  • Department of Pathology, The University of Texas-MD Anderson Cancer Center, Houston, TX 77030-4009, USA. · Pubmed 19718013
  • Department of Melanoma Medical Oncology and Department of Systems Biology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA. · Pubmed 19671763
2008
  • Department of Melanoma Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. · Pubmed 19011511
  • Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX 77030, USA. · Pubmed 18936790
  • The University of Texas Medical School at Houston, Houston, Texas, USA. · Pubmed 18798304
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. · Pubmed 18584354
  • The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. · Pubmed 18569391
  • Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA. · Pubmed 18383513
Probable:    University of the Pacific      
2015
  • Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA. · Department of Melanoma Medical Oncology, The University of Texas-MD Anderson Cancer Center, Houston, TX, USA. · Department of Medicine Statistics Core, University of California Los Angeles, Los Angeles, CA, USA. · St. Luke's Medical Center Cancer Center, Houston, TX, USA. · Department of Medicine, Division of Hematology/Oncology, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA, USA. · Department of Radiology, University of California Los Angeles, Los Angeles, CA, USA. · Department of Melanoma Medical Oncology, The University of Texas-MD Anderson Cancer Center, Houston, TX, USA; California Pacific Medical Center, San Francisco, CA, USA. · Department of Medicine, Division of Hematology/Oncology, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA, USA. Electronic address: · Pubmed 26364516
2016
  • Georgina V. Long, Melanoma Institute Australia; The University of Sydney; Richard F. Kefford, Melanoma Institute Australia; The University of Sydney; Macquarie University, Sydney; Westmead Hospital, Westmead; Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia; Jeffrey S. Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute/Tennessee Oncology; Kevin B. Kim, California Pacific Medical Center; Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, Karl Lewis, University of Colorado; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Jeffrey A. Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Elizabeth Cunningham, Merck; Peng Sun, Amy S. Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia, PA; Donald Lawrence and Kiran Patel, Incyte Corporation, Wilmington, DE; and Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA. · Georgina V. Long, Melanoma Institute Australia; The University of Sydney; Richard F. Kefford, Melanoma Institute Australia; The University of Sydney; Macquarie University, Sydney; Westmead Hospital, Westmead; Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia; Jeffrey S. Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute/Tennessee Oncology; Kevin B. Kim, California Pacific Medical Center; Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, Karl Lewis, University of Colorado; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Jeffrey A. Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Elizabeth Cunningham, Merck; Peng Sun, Amy S. Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia, PA; Donald Lawrence and Kiran Patel, Incyte Corporation, Wilmington, DE; and Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA. · Pubmed 26811525
2013
  • Paolo A. Ascierto, Ester Simeone, Instituto Nazionale Tumori Fondazione "G. Pascale," Napoli, Italy; David Minor, California Pacific Center for Melanoma Research and Treatment, San Francisco; Antoni Ribas, Jonsson Comprehensive Cancer Center, University of California, Los Angeles; Omid Hamid, Experimental Therapeutics/Immunotherapy, The Angeles Clinic and Research Institute, Los Angeles, CA; Anne O'Hagan, Niki Arya, Mary Guckert, Anne-Marie Martin, Jolly Mazumdar, Vicki L. Goodman, GlaxoSmithKline Oncology, Collegeville; Ravi Amaravadi, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Kevin B. Kim, The University of Texas MD Anderson Cancer Center, Houston, TX; Celeste Lebbe, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Paris, Université Paris Diderot, Paris; Jean-Jacques Grob, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Hôpital Timone, Marseille, France; Dirk Schadendorf, University Hospital Essen, Essen; Tabea Wilhelm, Uwe Trefzer, Charité-Universitätsmedizin, Berlin, Germany; Richard F. Kefford, Georgina V. Long, Westmead Hospital and Melanoma Institute Australia, University of Sydney, Sydney, Australia. · Pubmed 23918947
Show More
Specific Interests

In the titles of their published articles, experts often reveal their very specific interests.

Here are the titles of the 10 most recent articles (out of 80 total) written by Kevin B. Kim about Melanoma:

  • A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. 2017
  • A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma. 2017
  • Clinicopathological features and clinical outcomes associated with TP53 and BRAF 2017
  • Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. 2016
  • Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. 2016
  • Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. 2015
  • Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. 2015
  • Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. 2015
  • Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. 2015
  • Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report. 2015
Show List of Full Article Records
Google Searches

Learn more about Kevin B. Kim using the ready-made Google searches below.
This is essential! -- Publications never tell the whole story!

General Search:
University of California San Francisco
University of Texas Houston
University of the Pacific
Affiliation Timeline
Click for institutional directory in table below. (Not always available.)
What is this?
University of California San Francisco
2017
  • Beth Israel Deaconess Medical Center, Boston, Massachusetts. · Center for Cancer Precision Medicine/Dana-Farber Cancer Institute and the Broad Institute, Boston, Massachusetts. · Broad Institute of MIT and Harvard, Cambridge, Massachusetts. · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. · Dana Farber Cancer Institute, Boston, Massachusetts. · Massachusetts General Hospital, Boston, Massachusetts. · Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania. · California Pacific Medical Center Research Institute, San Francisco, California. · Vanderbilt-Ingram Cancer Center, Vanderbilt, Tennessee. · University Hospital, Zurich, Switzerland. · Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts. · Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. · Novartis Pharma AG, Basel, Switzerland. · Georgetown-Lombardi Comprehensive Cancer Center, Washington, District of Columbia. · Pubmed 28719152
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · Moffitt Cancer Center, 12902 USF Magnolia Dr., Tampa, FL, 33612, USA. · Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · California Pacific Medical Center, 2323 Sacramento St. #2, San Francisco, CA, 94115, USA. · The University of Texas Banner MD Anderson Cancer Center, 2946 E Banner Gateway Dr., Gilbert, AZ, 85234, USA. · Pubmed 28612140
  • Department of Medical Oncology, Moffitt Cancer Center, Tampa, Florida. · Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. · Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas. · Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. · Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. · Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. · Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. · Department of Internal Medicine, Baylor College of Medicine, Houston, Texas. · Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas. · Melanoma Clinical Research Program, California Pacific Medical Center, San Francisco, California. · Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas. · Pubmed 27911979
2016
  • Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston. · Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston. · Beth Israel Deaconess Medical Center, Boston, Massachusetts. · Departments of Pathology and Translational and Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston. · Broad Institute, Cambridge, Massachusetts. · Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston7Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston. · Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston. · Massachusetts General Hospital, Boston. · California Pacific Medical Center Research Institute, San Francisco. · Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston11Department of Systems Biology, University of Texas MD Anderson Cancer Center, Houston. · Pubmed 27124486
2015
  • Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA. · Department of Melanoma Medical Oncology, The University of Texas-MD Anderson Cancer Center, Houston, TX, USA. · Department of Medicine Statistics Core, University of California Los Angeles, Los Angeles, CA, USA. · St. Luke's Medical Center Cancer Center, Houston, TX, USA. · Department of Medicine, Division of Hematology/Oncology, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA, USA. · Department of Radiology, University of California Los Angeles, Los Angeles, CA, USA. · Department of Melanoma Medical Oncology, The University of Texas-MD Anderson Cancer Center, Houston, TX, USA; California Pacific Medical Center, San Francisco, CA, USA. · Department of Medicine, Division of Hematology/Oncology, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA, USA. Electronic address: · Pubmed 26364516
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Department of Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. · California Pacific Medical Center for Melanoma Research and Treatment, San Francisco Oncology Associates, 2333 Buchanan St., San Francisco, CA, 94115, USA. · Pubmed 25962795
2016
  • Georgina V. Long, Melanoma Institute Australia; The University of Sydney; Richard F. Kefford, Melanoma Institute Australia; The University of Sydney; Macquarie University, Sydney; Westmead Hospital, Westmead; Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia; Jeffrey S. Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute/Tennessee Oncology; Kevin B. Kim, California Pacific Medical Center; Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, Karl Lewis, University of Colorado; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Jeffrey A. Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Elizabeth Cunningham, Merck; Peng Sun, Amy S. Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia, PA; Donald Lawrence and Kiran Patel, Incyte Corporation, Wilmington, DE; and Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA. · Georgina V. Long, Melanoma Institute Australia; The University of Sydney; Richard F. Kefford, Melanoma Institute Australia; The University of Sydney; Macquarie University, Sydney; Westmead Hospital, Westmead; Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia; Jeffrey S. Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute/Tennessee Oncology; Kevin B. Kim, California Pacific Medical Center; Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, Karl Lewis, University of Colorado; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Jeffrey A. Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Elizabeth Cunningham, Merck; Peng Sun, Amy S. Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia, PA; Donald Lawrence and Kiran Patel, Incyte Corporation, Wilmington, DE; and Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA. · Pubmed 26811525
2014
  • Douglas B. Johnson and Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Keith T. Flaherty and Donald P. Lawrence, Massachusetts General Hospital Cancer Center, Boston MA; Jeffrey S. Weber and Geoffrey T. Gibney, Moffitt Cancer Center, Tampa, FL; Kevin B. Kim and Gerald S. Falchook, University of Texas MD Anderson Cancer Center, Houston, TX; Richard F. Kefford and Georgina V. Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales; Jonathan Cebon, Joint Ludwig-Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia; Omid Hamid, Angeles Clinic and Research Institute, Los Angeles; Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA; William H. Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Robert R. McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Karl Lewis and Rene Gonzalez, University of Colorado, Denver, CO; and Kiran Patel, Incyte, Wilmington, DE. · Douglas B. Johnson and Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Keith T. Flaherty and Donald P. Lawrence, Massachusetts General Hospital Cancer Center, Boston MA; Jeffrey S. Weber and Geoffrey T. Gibney, Moffitt Cancer Center, Tampa, FL; Kevin B. Kim and Gerald S. Falchook, University of Texas MD Anderson Cancer Center, Houston, TX; Richard F. Kefford and Georgina V. Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales; Jonathan Cebon, Joint Ludwig-Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia; Omid Hamid, Angeles Clinic and Research Institute, Los Angeles; Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA; William H. Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Robert R. McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Karl Lewis and Rene Gonzalez, University of Colorado, Denver, CO; and Kiran Patel, Incyte, Wilmington, DE. · Pubmed 25287827
2013
  • Paolo A. Ascierto, Ester Simeone, Instituto Nazionale Tumori Fondazione "G. Pascale," Napoli, Italy; David Minor, California Pacific Center for Melanoma Research and Treatment, San Francisco; Antoni Ribas, Jonsson Comprehensive Cancer Center, University of California, Los Angeles; Omid Hamid, Experimental Therapeutics/Immunotherapy, The Angeles Clinic and Research Institute, Los Angeles, CA; Anne O'Hagan, Niki Arya, Mary Guckert, Anne-Marie Martin, Jolly Mazumdar, Vicki L. Goodman, GlaxoSmithKline Oncology, Collegeville; Ravi Amaravadi, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Kevin B. Kim, The University of Texas MD Anderson Cancer Center, Houston, TX; Celeste Lebbe, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Paris, Université Paris Diderot, Paris; Jean-Jacques Grob, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Hôpital Timone, Marseille, France; Dirk Schadendorf, University Hospital Essen, Essen; Tabea Wilhelm, Uwe Trefzer, Charité-Universitätsmedizin, Berlin, Germany; Richard F. Kefford, Georgina V. Long, Westmead Hospital and Melanoma Institute Australia, University of Sydney, Sydney, Australia. · Pubmed 23918947
University of Texas Houston
2017
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · Moffitt Cancer Center, 12902 USF Magnolia Dr., Tampa, FL, 33612, USA. · Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · California Pacific Medical Center, 2323 Sacramento St. #2, San Francisco, CA, 94115, USA. · The University of Texas Banner MD Anderson Cancer Center, 2946 E Banner Gateway Dr., Gilbert, AZ, 85234, USA. · Pubmed 28612140
2015
  • The University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Sarah Cannon Research Institute at HealthONE, Denver, CO, USA. · Former employees of Eisai Inc., Woodcliff Lake, NJ, USA. · Eisai Inc., Oncology, Woodcliff Lake, NJ, USA. · Mary Crowley Cancer Research Center, Dallas, TX, USA. · Pubmed 26503473
  • The University of Texas MD Anderson Cancer Center, Houston, Texas. · The University of Texas MD Anderson Cancer Center, Houston, Texas. · Sarah Cannon Research Institute at HealthONE, Denver, Colorado. · Eisai Inc., Oncology, Woodcliff Lake, New Jersey. · Former employees of Eisai Inc., Woodcliff Lake, New Jersey. · Mary Crowley Cancer Research Center, Dallas, Texas. · Pubmed 26169970
  • Vanderbilt-Ingram Cancer Center, Vanderbilt University, 2220 Pierce Avenue #777, Nashville, TN 37232, USA. Electronic address: · Abramson Cancer Center and the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA. Electronic address: · Peter MacCallum Cancer Centre, 2 St Andrews Place, East Melbourne, Vic 3002, Australia. Electronic address: · Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA. Electronic address: · Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Electronic address: · Vanderbilt-Ingram Cancer Center, Vanderbilt University, 2220 Pierce Avenue #777, Nashville, TN 37232, USA. Electronic address: · Jonsson Comprehensive Cancer Center, University of California, Los Angeles, 11-934 Factor Bldg., 10833 Le Conte Ave., Los Angeles, CA 90095-1782, USA. Electronic address: · Peter MacCallum Cancer Centre, 2 St Andrews Place, East Melbourne, Vic 3002, Australia. Electronic address: · The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Electronic address: · Jonsson Comprehensive Cancer Center, University of California, Los Angeles, 11-934 Factor Bldg., 10833 Le Conte Ave., Los Angeles, CA 90095-1782, USA. Electronic address: · Plexxikon Inc., 91 Bolivar Drive, Berkeley, CA 94710, USA. Electronic address: · Plexxikon Inc., 91 Bolivar Drive, Berkeley, CA 94710, USA. Electronic address: · The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Electronic address: · Pubmed 25980594
  • Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA. · Department of Melanoma Medical Oncology, The University of Texas-MD Anderson Cancer Center, Houston, TX, USA. · Department of Medicine Statistics Core, University of California Los Angeles, Los Angeles, CA, USA. · St. Luke's Medical Center Cancer Center, Houston, TX, USA. · Department of Medicine, Division of Hematology/Oncology, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA, USA. · Department of Radiology, University of California Los Angeles, Los Angeles, CA, USA. · Department of Melanoma Medical Oncology, The University of Texas-MD Anderson Cancer Center, Houston, TX, USA; California Pacific Medical Center, San Francisco, CA, USA. · Department of Medicine, Division of Hematology/Oncology, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA, USA. Electronic address: · Pubmed 26364516
  • Department of Investigational Cancer Therapeutics - a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · Foundation Medicine, 150 Second Street, Cambridge, MA, 02141, USA. · Department of Investigational Cancer Therapeutics - a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · Department of Investigational Cancer Therapeutics - a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · Foundation Medicine, 150 Second Street, Cambridge, MA, 02141, USA. · Department of Investigational Cancer Therapeutics - a Phase I Clinical Trials Program, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. · Foundation Medicine, 150 Second Street, Cambridge, MA, 02141, USA. · Center for Personalized Cancer Therapy, Moores Cancer Center, The University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA, 92093, USA. · Pubmed 25886620
  • Department of Pathology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. · Department of Surgical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. · Department of Biostatistics, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. · Department of Melanoma Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. · Department of Pathology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA; Department of Dermatology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. · Department of Surgical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA; Department of Cancer Biology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. · Department of Melanoma Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA; Department of Systems Biology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. · Department of Hematopathology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. · Department of Systems Biology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. · Department of Experimental Therapeutics, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. · Department of Surgical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA; Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. · Department of Melanoma Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA; Department of Systems Biology, MD Anderson Cancer Center, The University of Texas, Houston, Texas, USA. Electronic address: · Pubmed 25148578
2014
  • Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ. · Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ. · Pubmed 25267741
  • Division of Cancer Medicine, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. · Melanoma Institute Australia and University of Sydney, New South Wales, Australia. Westmead Institute for Cancer Research, Westmead Millennium Institute, and Department of Medical Oncology, Westmead Hospital, Sydney, New South Wales, Australia. · Moores Cancer Center, University of California San Diego, La Jolla, California. · Division of Cancer Medicine, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. · GlaxoSmithKline Medicines Research Unit, Prince of Wales Hospital, Randwick, New South Wales, Australia. · Cancer Clinical Trials Unit, Royal Adelaide Hospital and University of Adelaide, Adelaide, South Australia, Australia. · Experimental Therapeutics/Immunotherapy, The Angeles Clinic and Research Institute, Los Angeles, California. · Drug Development Unit, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee. · Cancer Council Trials and Sir Charles Gairdner Hospital and University of Western Australia, Perth, Western Australia, Australia. · Division of Medical Oncology, New York University School of Medicine, New York, New York. · Prince of Wales Clinical School, University of New South Wales, Randwick, Australia. · GlaxoSmithKline Research and Development, Philadelphia, Pennsylvania and Research Triangle Park, North Carolina. · Melanoma Institute Australia and University of Sydney, New South Wales, Australia. Westmead Institute for Cancer Research, Westmead Millennium Institute, and Department of Medical Oncology, Westmead Hospital, Sydney, New South Wales, Australia. · Pubmed 24958809
  • University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: · Pubmed 24485878
2013
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. · Pubmed 23248257
2012
  • Department of Melanoma Medical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, Texas 77030, USA. · Pubmed 22668797
  • The University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Pubmed 22124101
2011
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. · Pubmed 21976540
2009
  • Department of Melanoma Medical Oncology, M. D. Anderson Cancer Center, The University of Texas, Houston 77030, Texas, USA. · Pubmed 19430405
  • Department of Melanoma Medical Oncology, Unit 430, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. · Pubmed 19002462
2014
  • University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Pubmed 24259661
  • Douglas B. Johnson and Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Keith T. Flaherty and Donald P. Lawrence, Massachusetts General Hospital Cancer Center, Boston MA; Jeffrey S. Weber and Geoffrey T. Gibney, Moffitt Cancer Center, Tampa, FL; Kevin B. Kim and Gerald S. Falchook, University of Texas MD Anderson Cancer Center, Houston, TX; Richard F. Kefford and Georgina V. Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales; Jonathan Cebon, Joint Ludwig-Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia; Omid Hamid, Angeles Clinic and Research Institute, Los Angeles; Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA; William H. Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Robert R. McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Karl Lewis and Rene Gonzalez, University of Colorado, Denver, CO; and Kiran Patel, Incyte, Wilmington, DE. · Douglas B. Johnson and Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Keith T. Flaherty and Donald P. Lawrence, Massachusetts General Hospital Cancer Center, Boston MA; Jeffrey S. Weber and Geoffrey T. Gibney, Moffitt Cancer Center, Tampa, FL; Kevin B. Kim and Gerald S. Falchook, University of Texas MD Anderson Cancer Center, Houston, TX; Richard F. Kefford and Georgina V. Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales; Jonathan Cebon, Joint Ludwig-Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia; Omid Hamid, Angeles Clinic and Research Institute, Los Angeles; Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA; William H. Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Robert R. McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Karl Lewis and Rene Gonzalez, University of Colorado, Denver, CO; and Kiran Patel, Incyte, Wilmington, DE. · Pubmed 25287827
  • aHealth Science Center, University of Oklahoma, Oklahoma City, Oklahoma Departments of bMelanoma Medical Oncology cPalliative Care and Rehabilitative Medicine dBiostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. · Pubmed 24743052
  • Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Pubmed 25030020
  • The University of Texas MD Anderson Cancer Center, Department of Melanoma Medical Oncology , Unit 430, 1515 Holcombe Blvd, Houston, TX 77030 , USA. · Pubmed 24720932
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. · Pubmed 24617955
  • Departments of *Pathology, †Melanoma Medical Oncology, ‡Head and Neck Surgery, and §Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas. · Pubmed 23812018
2013
  • The University of Texas MD Anderson Cancer Center, Dermatology, 1515 Holcombe Blvd, Houston, TX 77030, USA. · Pubmed 23800008
  • Paolo A. Ascierto, Ester Simeone, Instituto Nazionale Tumori Fondazione "G. Pascale," Napoli, Italy; David Minor, California Pacific Center for Melanoma Research and Treatment, San Francisco; Antoni Ribas, Jonsson Comprehensive Cancer Center, University of California, Los Angeles; Omid Hamid, Experimental Therapeutics/Immunotherapy, The Angeles Clinic and Research Institute, Los Angeles, CA; Anne O'Hagan, Niki Arya, Mary Guckert, Anne-Marie Martin, Jolly Mazumdar, Vicki L. Goodman, GlaxoSmithKline Oncology, Collegeville; Ravi Amaravadi, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Kevin B. Kim, The University of Texas MD Anderson Cancer Center, Houston, TX; Celeste Lebbe, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Paris, Université Paris Diderot, Paris; Jean-Jacques Grob, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Hôpital Timone, Marseille, France; Dirk Schadendorf, University Hospital Essen, Essen; Tabea Wilhelm, Uwe Trefzer, Charité-Universitätsmedizin, Berlin, Germany; Richard F. Kefford, Georgina V. Long, Westmead Hospital and Melanoma Institute Australia, University of Sydney, Sydney, Australia. · Pubmed 23918947
  • F. Stephen Hodi, Anita Giobbie-Hurder, Philip Friedlander, Jason J. Luke, Katherine A. Zukotynski, Jeffrey T. Yap, Annick D. Van den Abbeele, and George D. Demetri, Dana-Farber Cancer Institute; Jonathan A. Fletcher, Meijun Zhu, and Adrian Marino-Enriquez, Brigham and Women's Hospital; Donald Lawrence, Keith T. Flaherty, and David E. Fisher, Massachusetts General Hospital, Boston, MA; Christopher L. Corless, Michael C. Heinrich, and Carol Beadling, Portland Veterans Administration Medical Center and Oregon Health & Science University, Portland, OR; Philip Friedlander, Mount Sinai Medical Center, New York, NY; Rene Gonzalez, University of Colorado Cancer Center, Aurora, CO; Jeffrey S. Weber, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Thomas F. Gajewski, University of Chicago, Chicago, IL; Steven J. O'Day, Beverly Hills Cancer Center, Beverly Hills, CA; Kevin B. Kim, The University of Texas MD Anderson Cancer Center, Houston, TX; Frances A. Collichio, The University of North Carolina at Chapel Hill, Chapel Hill, NC; and Marc S. Ernstoff, Geisel School of Medicine and Norris Cotton Cancer Center, Hanover, NH. · Pubmed 23775962
  • M.D. Anderson Cancer Center, University of Texas, Houston, TX 77054, USA. · Pubmed 23603862
  • Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. · Pubmed 22972589
  • Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. · Pubmed 23922205
  • Departments of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. · Pubmed 23358426
2012
  • The University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Pubmed 22394161
  • Departments of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. · Pubmed 23032743
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. · Pubmed 22809251
  • Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. · Pubmed 22805292
  • Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. · Pubmed 22608338
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. · Pubmed 22274951
  • Departments of Melanoma Medical Oncology, Systems Biology, Biostatistics, Pathology, Experimental Therapeutics, and Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. · Pubmed 22223528
  • Department of Melanoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas 77054, USA. · Pubmed 22584956
  • The University of Texas-Houston Medical School, Houston, TX, USA. · Pubmed 22395592
  • Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. · Pubmed 22180178
2011
  • Departments of aMelanoma Medical Oncology bBioinformatics cNursing, MD, Anderson Cancer Center, University of Texas, Houston, Texas, USA. · Pubmed 21102360
  • Department of Melanoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA. · Pubmed 21738104
  • Department of Melanoma Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA. · Pubmed 21632855
  • Department of Melanoma Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. · Pubmed 20978276
  • Department of Melanoma/Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. · Pubmed 21169870
  • Departments of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. · Pubmed 21150567
  • Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77054, USA. · Pubmed 20960525
2010
  • Department of Melanoma Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA. · Pubmed 20881508
  • Department of Melanoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA. · Pubmed 20859231
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. · Pubmed 19952963
2009
  • Department of Melanoma Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, 1515 Holcombe Building, Unit 430, Houston, TX 77030, USA. · Pubmed 19521262
  • Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA. · Pubmed 19506454
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. · Pubmed 19440934
  • Department of Pathology, The University of Texas-MD Anderson Cancer Center, Houston, TX 77030-4009, USA. · Pubmed 19718013
  • Department of Melanoma Medical Oncology and Department of Systems Biology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA. · Pubmed 19671763
2008
  • Department of Melanoma Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. · Pubmed 19011511
  • Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX 77030, USA. · Pubmed 18936790
  • The University of Texas Medical School at Houston, Houston, Texas, USA. · Pubmed 18798304
  • Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. · Pubmed 18584354
  • The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. · Pubmed 18569391
  • Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA. · Pubmed 18383513
University of the Pacific
2015
  • Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA. · Department of Melanoma Medical Oncology, The University of Texas-MD Anderson Cancer Center, Houston, TX, USA. · Department of Medicine Statistics Core, University of California Los Angeles, Los Angeles, CA, USA. · St. Luke's Medical Center Cancer Center, Houston, TX, USA. · Department of Medicine, Division of Hematology/Oncology, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA, USA. · Department of Radiology, University of California Los Angeles, Los Angeles, CA, USA. · Department of Melanoma Medical Oncology, The University of Texas-MD Anderson Cancer Center, Houston, TX, USA; California Pacific Medical Center, San Francisco, CA, USA. · Department of Medicine, Division of Hematology/Oncology, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, CA, USA. Electronic address: · Pubmed 26364516
2016
  • Georgina V. Long, Melanoma Institute Australia; The University of Sydney; Richard F. Kefford, Melanoma Institute Australia; The University of Sydney; Macquarie University, Sydney; Westmead Hospital, Westmead; Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia; Jeffrey S. Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute/Tennessee Oncology; Kevin B. Kim, California Pacific Medical Center; Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, Karl Lewis, University of Colorado; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Jeffrey A. Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Elizabeth Cunningham, Merck; Peng Sun, Amy S. Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia, PA; Donald Lawrence and Kiran Patel, Incyte Corporation, Wilmington, DE; and Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA. · Georgina V. Long, Melanoma Institute Australia; The University of Sydney; Richard F. Kefford, Melanoma Institute Australia; The University of Sydney; Macquarie University, Sydney; Westmead Hospital, Westmead; Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia; Jeffrey S. Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute/Tennessee Oncology; Kevin B. Kim, California Pacific Medical Center; Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, Karl Lewis, University of Colorado; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Jeffrey A. Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Elizabeth Cunningham, Merck; Peng Sun, Amy S. Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia, PA; Donald Lawrence and Kiran Patel, Incyte Corporation, Wilmington, DE; and Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA. · Pubmed 26811525
2013
  • Paolo A. Ascierto, Ester Simeone, Instituto Nazionale Tumori Fondazione "G. Pascale," Napoli, Italy; David Minor, California Pacific Center for Melanoma Research and Treatment, San Francisco; Antoni Ribas, Jonsson Comprehensive Cancer Center, University of California, Los Angeles; Omid Hamid, Experimental Therapeutics/Immunotherapy, The Angeles Clinic and Research Institute, Los Angeles, CA; Anne O'Hagan, Niki Arya, Mary Guckert, Anne-Marie Martin, Jolly Mazumdar, Vicki L. Goodman, GlaxoSmithKline Oncology, Collegeville; Ravi Amaravadi, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Kevin B. Kim, The University of Texas MD Anderson Cancer Center, Houston, TX; Celeste Lebbe, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Paris, Université Paris Diderot, Paris; Jean-Jacques Grob, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Hôpital Timone, Marseille, France; Dirk Schadendorf, University Hospital Essen, Essen; Tabea Wilhelm, Uwe Trefzer, Charité-Universitätsmedizin, Berlin, Germany; Richard F. Kefford, Georgina V. Long, Westmead Hospital and Melanoma Institute Australia, University of Sydney, Sydney, Australia. · Pubmed 23918947
Yale University
2014
  • Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ. · Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ. · Pubmed 25267741
2014
  • Douglas B. Johnson and Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Keith T. Flaherty and Donald P. Lawrence, Massachusetts General Hospital Cancer Center, Boston MA; Jeffrey S. Weber and Geoffrey T. Gibney, Moffitt Cancer Center, Tampa, FL; Kevin B. Kim and Gerald S. Falchook, University of Texas MD Anderson Cancer Center, Houston, TX; Richard F. Kefford and Georgina V. Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales; Jonathan Cebon, Joint Ludwig-Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia; Omid Hamid, Angeles Clinic and Research Institute, Los Angeles; Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA; William H. Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Robert R. McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Karl Lewis and Rene Gonzalez, University of Colorado, Denver, CO; and Kiran Patel, Incyte, Wilmington, DE. · Douglas B. Johnson and Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Keith T. Flaherty and Donald P. Lawrence, Massachusetts General Hospital Cancer Center, Boston MA; Jeffrey S. Weber and Geoffrey T. Gibney, Moffitt Cancer Center, Tampa, FL; Kevin B. Kim and Gerald S. Falchook, University of Texas MD Anderson Cancer Center, Houston, TX; Richard F. Kefford and Georgina V. Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales; Jonathan Cebon, Joint Ludwig-Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia; Omid Hamid, Angeles Clinic and Research Institute, Los Angeles; Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA; William H. Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Robert R. McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Karl Lewis and Rene Gonzalez, University of Colorado, Denver, CO; and Kiran Patel, Incyte, Wilmington, DE. · Pubmed 25287827
New York University
2014
  • Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ. · Patrick A. Ott and Anna C. Pavlick, New York University Cancer Institute, New York, NY; Omid Hamid and Peter D. Boasberg, The Angeles Clinic and Research Institute, Los Angeles, CA; Harriet Kluger and Mario Sznol, Yale Cancer Center, New Haven, CT; Kevin B. Kim and Patrick Hwu, University of Texas MD Anderson Cancer Center, Houston, TX; Ronit Simantov, Elizabeth Crowley, Jennifer A. Green, Thomas Hawthorne, and Thomas A. Davis, Celldex Therapeutics, Hampton, NJ. · Pubmed 25267741
35 Other Locations Show
Yearly article counts 03271214158577
 
Remember this Person You can save this page -- like a bookmark -- so it's remembered for you on the Expertscape "Saved Pages" page, which is always easily available from the page-top menu bar throughout the site.